---
title: "Many listed companies have taken repurchase actions in the first month of the new year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274571997.md"
description: "Since 2026, the trend of share buybacks among listed companies has continued. In January, several A-share companies implemented buybacks, including BUCHANG PHARMA and Xingfa Chem. Huasheng Lithium Battery, RemeGen, and Yiyi Co., Ltd. adjusted their buyback prices due to stock prices exceeding the buyback limit. The main reason for the companies' buybacks is based on confidence in future development prospects, with repurchased shares often used for employee stock ownership plans or equity incentives"
datetime: "2026-02-02T23:53:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274571997.md)
  - [en](https://longbridge.com/en/news/274571997.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274571997.md)
---

# Many listed companies have taken repurchase actions in the first month of the new year

Since 2026, the trend of share buybacks by listed companies has continued. Since January, several A-share companies have implemented buybacks with "real money." Among them, BUCHANG PHARMA and Xingfa Chem quickly executed their buyback plans after disclosing them in January; Huasheng Lithium Battery, RemeGen, and Yiyi Co., Ltd. have significantly raised their buyback prices to ensure the smooth implementation of their buyback plans, as their stock prices have recently exceeded the upper limit of the buyback price. It can be seen that "confidence in the company's future development prospects and a fundamental judgment of the company's intrinsic value" have become important reasons for many companies to implement buybacks; the shares repurchased by the company are mostly planned for employee stock ownership plans or equity incentives. (Shanghai Securities Journal)

### Related Stocks

- [603858.CN](https://longbridge.com/en/quote/603858.CN.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [600141.CN](https://longbridge.com/en/quote/600141.CN.md)

## Related News & Research

- [Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer](https://longbridge.com/en/news/296098241.md)
- [Naturgy, Greene start pilot plant converting industrial waste, biomass into biomethane](https://longbridge.com/en/news/296196685.md)
- [07:20 ETAizen Enters into Collaboration with San Diego Biopharma to Advance Oral Biologics](https://longbridge.com/en/news/296000080.md)
- [VibroSense wins Japan patent for chemotherapy-induced neuropathy biomarker](https://longbridge.com/en/news/295890805.md)
- [EXCLUSIVE-US FTC probing health records company Epic Systems](https://longbridge.com/en/news/295968285.md)